Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25182947 | 1.00 | CBLB (0.67) | CBLBCBLC | |
| SCHEMBL30374389 | 1.00 | CBLB (0.67) | CBLBCBLC | |
| SCHEMBL25179597 | 1.00 | CBLB (0.67) | CBLBCBLC | |
| SCHEMBL25179596 | 1.00 | CBLB (0.67) | CBLBCBLC | |
| SCHEMBL30374418 | 1.00 | CBLB (0.67) | CBLBCBLC | |
| SCHEMBL25310689 | 0.93 | CBLB (0.67) | CBLBCBLC | |
| SCHEMBL25186664 | 0.93 | CBLB (0.67) | CBLBCBLC | |
| SCHEMBL25186663 | 0.93 | CBLB (0.67) | CBLBCBLC | |
| SCHEMBL25310423 | 0.93 | CBLB (0.67) | CBLBCBLC | |
| SCHEMBL25192814 | 0.93 | CBLB (0.67) | CBLBCBLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187709-B2 | Lactams as CBL-B inhibitors selective over C-CBL | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4426691-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | Genentech, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20230212153-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | GENENTECH, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2023081853-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | GENENTECH, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212153-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | CBL, CBLB, CBLC | CBLB 2/4885CBLC 3/4885 |
| US-12187709-B2 | Lactams as CBL-B inhibitors selective over C-CBL | CBL, CBLB, CBLC | CBLB 2/4885CBLC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.